MECOM-driven AML and AML transformed from myeloproliferative neoplasms (post-MPN AML) frequently exhibit aggressive clonal evolution, profound chemoresistance, and extensive remodeling of the bone marrow microenvironment. The gene discussed is MECOM; the disease is myeloproliferative neoplasm.